181 related articles for article (PubMed ID: 26916006)
1. HSP90 and Immune Modulation in Cancer.
Graner MW
Adv Cancer Res; 2016; 129():191-224. PubMed ID: 26916006
[TBL] [Abstract][Full Text] [Related]
2. Emerging Roles of Extracellular Hsp90 in Cancer.
Wong DS; Jay DG
Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
[TBL] [Abstract][Full Text] [Related]
3. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.
Proia DA; Kaufmann GF
Cancer Immunol Res; 2015 Jun; 3(6):583-9. PubMed ID: 25948551
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
5. EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity.
Yun TJ; Harning EK; Giza K; Rabah D; Li P; Arndt JW; Luchetti D; Biamonte MA; Shi J; Lundgren K; Manning A; Kehry MR
J Immunol; 2011 Jan; 186(1):563-75. PubMed ID: 21131419
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
7. Dual role of heat shock proteins as regulators of apoptosis and innate immunity.
Joly AL; Wettstein G; Mignot G; Ghiringhelli F; Garrido C
J Innate Immun; 2010; 2(3):238-47. PubMed ID: 20375559
[TBL] [Abstract][Full Text] [Related]
8. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs JS
Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
[TBL] [Abstract][Full Text] [Related]
9. GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development.
Wu BX; Hong F; Zhang Y; Ansa-Addo E; Li Z
Adv Cancer Res; 2016; 129():165-90. PubMed ID: 26916005
[TBL] [Abstract][Full Text] [Related]
10. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
11. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
12. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
13. Hsp90: the vulnerable chaperone.
Chiosis G; Vilenchik M; Kim J; Solit D
Drug Discov Today; 2004 Oct; 9(20):881-8. PubMed ID: 15475321
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
15. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Jhaveri K; Modi S
Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
De Mattos-Arruda L; Cortes J
Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HSP90 molecular chaperones: moving into the clinic.
Garcia-Carbonero R; Carnero A; Paz-Ares L
Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
[TBL] [Abstract][Full Text] [Related]
19. Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors.
Yuno A; Lee MJ; Lee S; Tomita Y; Rekhtman D; Moore B; Trepel JB
Methods Mol Biol; 2018; 1709():423-441. PubMed ID: 29177675
[TBL] [Abstract][Full Text] [Related]
20. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]